Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The role of Budesonide-MMX in active ulcerative colitis.

Gionchetti P, Praticò C, Rizzello F, Calafiore A, Capozzi N, Campieri M, Calabrese C.

Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):215-22. doi: 10.1586/17474124.2014.887437. Review.

PMID:
24502535
2.

Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.

Danese S, Siegel CA, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2014 May;39(10):1095-103. doi: 10.1111/apt.12712. Review.

3.

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ.

Gut. 2014 Mar;63(3):433-41. doi: 10.1136/gutjnl-2012-304258.

4.

Novel extended release budesonide formulation for treatment of ulcerative colitis.

Farkas K, Molnár T.

Expert Opin Pharmacother. 2014 Jan;15(1):131-7. doi: 10.1517/14656566.2014.860444. Review.

PMID:
24219763
5.

Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.

Hoy SM.

Drugs. 2015 May;75(8):879-86. doi: 10.1007/s40265-015-0396-8. Review.

PMID:
25920500
6.

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis.

Lichtenstein GR.

Dig Dis Sci. 2016 Feb;61(2):358-70. doi: 10.1007/s10620-015-3897-0. Review.

7.

Budesonide multi-matrix system formulation for treating ulcerative colitis.

Prantera C, Scribano ML.

Expert Opin Pharmacother. 2014 Apr;15(6):741-3. doi: 10.1517/14656566.2014.884072.

PMID:
24484392
8.

Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.

D'Haens GR, Kovács A, Vergauwe P, Nagy F, Molnár T, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Binelli D, Di Stefano AF, Marteau P.

J Crohns Colitis. 2010 Jun;4(2):153-60. doi: 10.1016/j.crohns.2009.09.007.

PMID:
21122499
9.

Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.

Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED 2nd.

Gastroenterology. 2012 Nov;143(5):1218-26.e1-2. doi: 10.1053/j.gastro.2012.08.003.

PMID:
22892337
10.

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.

Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S.

Aliment Pharmacol Ther. 2015 Mar;41(5):409-18. doi: 10.1111/apt.13076.

11.

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis.

Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ.

J Crohns Colitis. 2015 Sep;9(9):738-46. doi: 10.1093/ecco-jcc/jjv101.

12.

Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?

De Cassan C, Fiorino G, Danese S.

Dig Dis. 2012;30(4):368-75. doi: 10.1159/000338128. Review.

PMID:
22796798
13.

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.

D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R.

Aliment Pharmacol Ther. 2006 Oct 1;24(7):1087-97.

14.

Budesonide for ulcerative colitis.

Marín-Jiménez I, Peña AS.

Rev Esp Enferm Dig. 2006 May;98(5):362-73. Review. English, Spanish.

15.

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis.

Iborra M, Alvarez-Sotomayor D, Nos P.

Clin Exp Gastroenterol. 2014 Feb 5;7:39-46. doi: 10.2147/CEG.S34715. Review.

16.

Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.

Gross V.

Expert Opin Pharmacother. 2008 May;9(7):1257-65. doi: 10.1517/14656566.9.7.1257. Review.

PMID:
18422482
17.
18.

Budesonide in the treatment of inflammatory bowel disease.

Silverman J, Otley A.

Expert Rev Clin Immunol. 2011 Jul;7(4):419-28. doi: 10.1586/eci.11.34. Review.

PMID:
21790284
19.

Oral beclomethasone dipropionate: a critical review of its use in the management of ulcerative colitis and Crohn's disease.

Fascì Spurio F, Aratari A, Margagnoni G, Doddato MT, Chiesara F, Papi C.

Curr Clin Pharmacol. 2012 May;7(2):131-6. Review.

PMID:
22432845
20.

Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.

Kolkman JJ, Möllmann HW, Möllmann AC, Penã AS, Greinwald R, Tauschel HD, Hochhaus G.

Drugs Today (Barc). 2004 Jul;40(7):589-601.

PMID:
15510233
Items per page

Supplemental Content

Support Center